{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T03:12:30Z","timestamp":1784257950128,"version":"3.55.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.beem.2024.101921","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T06:39:49Z","timestamp":1722667189000},"page":"101921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Gender-affirming hormone treatment modalities for transfemale &amp; non-binary transfeminine individuals: A UK perspective"],"prefix":"10.1016","volume":"38","author":[{"given":"Rebecca C.","family":"Sagar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Millson-Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2024.101921_bib1","doi-asserted-by":"crossref","unstructured":"Heath, L. and S. Bunn, Factors shaping gender incongruence and dysphoria, and impact on health services. 2023.","DOI":"10.58248\/PB53"},{"issue":"1","key":"10.1016\/j.beem.2024.101921_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2023-000499","article-title":"Transgender identity in young people and adults recorded in UK primary care electronic patient records: retrospective, dynamic, cohort study","volume":"2","author":"McKechnie","year":"2023","journal-title":"BMJ Med"},{"key":"10.1016\/j.beem.2024.101921_bib3","unstructured":"Statistics, Of.N., Gender identity, England and Wales: Census 2021, O.f.N. Statistics, Editor. 2023."},{"key":"10.1016\/j.beem.2024.101921_bib4","unstructured":"Barton, C., 2021 census: What do we know about the LGBT+ population?, U.P. House of Commons Library, Editor. 2023."},{"issue":"3","key":"10.1016\/j.beem.2024.101921_bib5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.molmed.2012.12.007","article-title":"Estrogen synthesis and signaling pathways during aging: from periphery to brain","volume":"19","author":"Cui","year":"2013","journal-title":"Trends Mol Med"},{"issue":"4","key":"10.1016\/j.beem.2024.101921_bib6","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1210\/er.2008-0016","article-title":"History of aromatase: saga of an important biological mediator and therapeutic target","volume":"30","author":"Santen","year":"2009","journal-title":"Endocr Rev"},{"issue":"6","key":"10.1016\/j.beem.2024.101921_bib7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/tre.663","article-title":"Hormone management of trans women","volume":"9","author":"Coxon","year":"2018","journal-title":"Trends Urol Men'S Health"},{"issue":"8","key":"10.1016\/j.beem.2024.101921_bib8","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1210\/jcem.85.8.6710","article-title":"Effects of sex steroid deprivation\/administration on hair growth and skin sebum production in transsexual males and females","volume":"85","author":"Giltay","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.beem.2024.101921_bib9","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1210\/jc.2017-01658","article-title":"Endocrine treatment of gender-dysphoric\/gender-incongruent persons: an endocrine society clinical practice guideline","volume":"102","author":"Hembree","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.beem.2024.101921_bib10","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1210\/jc.2016-1276","article-title":"Cross-sex hormone treatment and psychobiological changes in transsexual persons: two-year follow-up data","volume":"101","author":"Fisher","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.beem.2024.101921_bib11","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1097\/NMD.0000000000000046","article-title":"Hormonal therapy is associated with better self-esteem, mood, and quality of life in transsexuals","volume":"201","author":"Gorin-Lazard","year":"2013","journal-title":"J Nerv Ment Dis"},{"issue":"5","key":"10.1016\/j.beem.2024.101921_bib12","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/jsm.12487","article-title":"Clinical review: breast development in trans women receiving cross-sex hormones","volume":"11","author":"Wierckx","year":"2014","journal-title":"J Sex Med"},{"issue":"2","key":"10.1016\/j.beem.2024.101921_bib13","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/00006534-199908000-00040","article-title":"Augmentation mammaplasty in male-to-female transsexuals","volume":"104","author":"Kanhai","year":"1999","journal-title":"Plast Reconstr Surg"},{"issue":"2","key":"10.1016\/j.beem.2024.101921_bib14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/BF01542220","article-title":"Physical and hormonal evaluation of transsexual patients: a longitudinal study","volume":"15","author":"Meyer","year":"1986","journal-title":"Arch Sex Behav"},{"issue":"12","key":"10.1016\/j.beem.2024.101921_bib15","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1210\/jc.2012-2030","article-title":"Predictive markers for mammoplasty and a comparison of side effect profiles in transwomen taking various hormonal regimens","volume":"97","author":"Seal","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.beem.2024.101921_bib16","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/01.GME.0000055522.67459.89","article-title":"A physiologic role for testosterone in limiting estrogenic stimulation of the breast","volume":"10","author":"Dimitrakakis","year":"2003","journal-title":"Menopause"},{"issue":"1","key":"10.1016\/j.beem.2024.101921_bib17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/sj.bjc.6601517","article-title":"Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study","volume":"90","author":"Zeleniuch-Jacquotte","year":"2004","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.beem.2024.101921_bib18","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1677\/erc.1.01038","article-title":"Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition","volume":"12","author":"Kaaks","year":"2005","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"10.1016\/j.beem.2024.101921_bib19","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1111\/jsm.13022","article-title":"Testicular functions and clinical characterization of patients with gender dysphoria (GD) undergoing sex reassignment surgery (SRS)","volume":"12","author":"Schneider","year":"2015","journal-title":"J Sex Med"},{"issue":"3","key":"10.1016\/j.beem.2024.101921_bib20","first-page":"347","article-title":"The effect of estrogen therapy on spermatogenesis in transgender women","volume":"2","author":"Sinha","year":"2021","journal-title":"F S Rep"},{"issue":"5","key":"10.1016\/j.beem.2024.101921_bib21","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1046\/j.1365-2265.2003.01753.x","article-title":"Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects","volume":"58","author":"Elbers","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"10.1016\/j.beem.2024.101921_bib22","doi-asserted-by":"crossref","DOI":"10.1111\/and.12660","article-title":"Cross-sex hormone therapy in transgender persons affects total body weight, body fat and lean body mass: a meta-analysis","volume":"49","author":"Klaver","year":"2017","journal-title":"Andrologia"},{"issue":"4","key":"10.1016\/j.beem.2024.101921_bib23","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7326\/M17-2785","article-title":"Cross-sex hormones and acute cardiovascular events in transgender persons: a cohort study","volume":"169","author":"Getahun","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.beem.2024.101921_bib24","article-title":"Effects of gender affirming hormone therapy on body mass index in transgender individuals: a longitudinal cohort study","volume":"21","author":"Suppakitjanusant","year":"2020","journal-title":"J Clin Transl Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2024.101921_bib25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4158\/EP-2020-0414","article-title":"Serum hormone concentrations in transgender individuals receiving gender-affirming hormone therapy: a longitudinal retrospective cohort study","volume":"27","author":"Chantrapanichkul","year":"2021","journal-title":"Endocr Pr"},{"issue":"9S","key":"10.1016\/j.beem.2024.101921_bib26","doi-asserted-by":"crossref","first-page":"18S","DOI":"10.1002\/j.1552-4604.1995.tb04143.x","article-title":"Pharmacokinetic and pharmacologic variation between different estrogen products","volume":"35","author":"O'Connell","year":"1995","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.beem.2024.101921_bib27","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S2213-8587(16)30319-9","article-title":"Oestrogen and anti-androgen therapy for transgender women","volume":"5","author":"Tangpricha","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2024.101921_bib28","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/cen.14329","article-title":"A systematic review of antiandrogens and feminization in transgender women","volume":"94","author":"Angus","year":"2021","journal-title":"Clin Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2024.101921_bib29","doi-asserted-by":"crossref","first-page":"R49","DOI":"10.1530\/EJE-21-0059","article-title":"Management of endocrine disease: optimal feminizing hormone treatment in transgender people","volume":"185","author":"Glintborg","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.beem.2024.101921_bib30","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1210\/jcem-41-4-777","article-title":"Effect of spironolactone on sex hormones in man","volume":"41","author":"Stripp","year":"1975","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2024.101921_bib31","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/BF01579291","article-title":"Spironolactone with physiological female steroids for presurgical therapy of male-to-female transsexualism","volume":"18","author":"Prior","year":"1989","journal-title":"Arch Sex Behav"},{"issue":"7","key":"10.1016\/j.beem.2024.101921_bib32","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1093\/brain\/awy108","article-title":"The occurrence of benign brain tumours in transgender individuals during cross-sex hormone treatment","volume":"141","author":"Nota","year":"2018","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.beem.2024.101921_bib33","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s40360-023-00724-4","article-title":"Addition of progesterone to feminizing gender-affirming hormone therapy in transgender individuals for breast development: a randomized controlled trial","volume":"24","author":"Dijkman","year":"2023","journal-title":"BMC Pharmacol Toxicol"},{"issue":"19","key":"10.1016\/j.beem.2024.101921_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13194972","article-title":"Type 1 nuclear receptor activity in breast cancer: translating preclinical insights to the clinic","volume":"13","author":"Kumar","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.beem.2024.101921_bib35","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4331\/wjbc.v13.i3.66","article-title":"Progesterone in gender-affirming therapy of trans women","volume":"13","author":"Milionis","year":"2022","journal-title":"World J Biol Chem"},{"key":"10.1016\/j.beem.2024.101921_bib36","doi-asserted-by":"crossref","first-page":"m3873","DOI":"10.1136\/bmj.m3873","article-title":"Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases","volume":"371","author":"Vinogradova","year":"2020","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.beem.2024.101921_bib37","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2174\/0929867003374967","article-title":"Cardiovascular disease risk and hormone replacement therapy (HRT): a review based on randomised, controlled studies in postmenopausal women","volume":"7","author":"Baal","year":"2000","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.beem.2024.101921_bib38","unstructured":"NG23, N.g., Menopause: Diagnosis and Management. 2023."},{"issue":"688","key":"10.1016\/j.beem.2024.101921_bib39","doi-asserted-by":"crossref","first-page":"540","DOI":"10.3399\/bjgp19X706169","article-title":"The dangers of compounded bioidentical hormone replacement therapy","volume":"69","author":"Newson","year":"2019","journal-title":"Br J Gen Pr"},{"issue":"1","key":"10.1016\/j.beem.2024.101921_bib40","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1177\/2053369119876490","article-title":"Progestogens are the problem in hormone replacement therapy: time to reappraise their use","volume":"26","author":"Manyonda","year":"2020","journal-title":"Post Reprod Health"},{"issue":"Suppl 1","key":"10.1016\/j.beem.2024.101921_bib41","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1080\/26895269.2022.2100644","article-title":"Standards of care for the health of transgender and gender diverse people, Version 8","volume":"23","author":"Coleman","year":"2022","journal-title":"Int J Transgend Health"},{"issue":"12","key":"10.1016\/j.beem.2024.101921_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8122203","article-title":"Hyperprolactinaemia","volume":"8","author":"Samperi","year":"2019","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.beem.2024.101921_bib43","first-page":"583","article-title":"Prolactin levels and pituitary enlargement in hormone-treated male-to-female transsexuals","volume":"28","author":"Asscheman","year":"1988","journal-title":"Clin Endocrinol"},{"issue":"2","key":"10.1016\/j.beem.2024.101921_bib44","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2265.1985.tb01081.x","article-title":"Follow-up of prolactin levels in long-term oestrogen-treated male-to-female transsexuals with regard to prolactinoma induction","volume":"22","author":"Gooren","year":"1985","journal-title":"Clin Endocrinol"},{"issue":"4","key":"10.1016\/j.beem.2024.101921_bib45","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/15532739.2020.1819505","article-title":"Effects of antiandrogens on prolactin levels among transgender women on estrogen therapy: a systematic review","volume":"21","author":"Wilson","year":"2020","journal-title":"Int J Transgend Health"},{"issue":"8","key":"10.1016\/j.beem.2024.101921_bib46","doi-asserted-by":"crossref","first-page":"883","DOI":"10.4158\/EP-2020-0032","article-title":"Differential endocrine and metabolic effects of testosterone suppressive agents in transgender women","volume":"26","author":"Sofer","year":"2020","journal-title":"Endocr Pr"},{"issue":"2","key":"10.1016\/j.beem.2024.101921_bib47","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/liv.12899","article-title":"Cyproterone acetate induces a wide spectrum of acute liver damage including corticosteroid-responsive hepatitis: report of 22 cases","volume":"36","author":"Bessone","year":"2016","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.beem.2024.101921_bib48","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1046\/j.0004-8666.2003.00068.x","article-title":"Effect of oestrogen replacement therapy on serum lipid profile","volume":"43","author":"Nanda","year":"2003","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"4","key":"10.1016\/j.beem.2024.101921_bib49","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2337\/cd21-0011","article-title":"Considerations for transgender people with diabetes","volume":"39","author":"Moverley","year":"2021","journal-title":"Clin Diabetes"},{"issue":"1","key":"10.1016\/j.beem.2024.101921_bib50","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41440-022-01067-z","article-title":"Incidence of hypertension in young transgender people after a 5-year follow-up: association with gender-affirming hormonal therapy","volume":"46","author":"Martinez-Martin","year":"2023","journal-title":"Hypertens Res"},{"issue":"3","key":"10.1016\/j.beem.2024.101921_bib51","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41440-022-01162-1","article-title":"Blood pressure changes with gender-affirming hormone therapy in transgender people","volume":"46","author":"Satoh","year":"2023","journal-title":"Hypertens Res"},{"issue":"12","key":"10.1016\/j.beem.2024.101921_bib52","doi-asserted-by":"crossref","first-page":"951","DOI":"10.7326\/0003-4819-133-12-200012190-00010","article-title":"Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham study","volume":"133","author":"Amin","year":"2000","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.beem.2024.101921_bib53","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1210\/jc.2017-01642","article-title":"Effect of sex steroids on the bone health of transgender individuals: a systematic review and meta-analysis","volume":"102","author":"Singh-Ospina","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101921_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.761255","article-title":"The pathological mechanisms of estrogen-induced cholestasis: current perspectives","volume":"12","author":"Zu","year":"2021","journal-title":"Front Pharm"},{"issue":"3","key":"10.1016\/j.beem.2024.101921_bib55","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1001\/jama.293.3.330","article-title":"Effect of estrogen therapy on gallbladder disease","volume":"293","author":"Cirillo","year":"2005","journal-title":"Jama"},{"issue":"3","key":"10.1016\/j.beem.2024.101921_bib56","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1046\/j.1365-2265.1997.2601068.x","article-title":"Mortality and morbidity in transsexual subjects treated with cross-sex hormones","volume":"47","author":"van Kesteren","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"10.1016\/j.beem.2024.101921_bib57","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1055\/s-2005-865900","article-title":"Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist","volume":"113","author":"Dittrich","year":"2005","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"7","key":"10.1016\/j.beem.2024.101921_bib58","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/and.12150","article-title":"Venous thrombo-embolism as a complication of cross-sex hormone treatment of male-to-female transsexual subjects: a review","volume":"46","author":"Asscheman","year":"2014","journal-title":"Andrologia"},{"issue":"11","key":"10.1016\/j.beem.2024.101921_bib59","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1210\/jc.2017-01643","article-title":"Sex steroids and cardiovascular outcomes in transgender individuals: a systematic review and meta-analysis","volume":"102","author":"Maraka","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.beem.2024.101921_bib60","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1530\/EJE-10-1038","article-title":"A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones","volume":"164","author":"Asscheman","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.beem.2024.101921_bib61","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1089\/lgbt.2014.0123","article-title":"Breast cancer in transgender veterans: a ten-case series","volume":"2","author":"Brown","year":"2015","journal-title":"LGBT Health"},{"key":"10.1016\/j.beem.2024.101921_bib62","doi-asserted-by":"crossref","first-page":"l1652","DOI":"10.1136\/bmj.l1652","article-title":"Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands","volume":"365","author":"de Blok","year":"2019","journal-title":"Bmj"},{"key":"10.1016\/j.beem.2024.101921_bib63","unstructured":"UK, C.R. Breast Cancer Statistics. 2024 [cited 2024 May 2024]."},{"issue":"4","key":"10.1016\/j.beem.2024.101921_bib64","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/S0022-5347(01)65584-8","article-title":"Effects of estrogens only on the prostates of aging men","volume":"156","author":"van Kesteren","year":"1996","journal-title":"J Urol"},{"issue":"8","key":"10.1016\/j.beem.2024.101921_bib65","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41562-023-01605-w","article-title":"A systematic review of psychosocial functioning changes after gender-affirming hormone therapy among transgender people","volume":"7","author":"Doyle","year":"2023","journal-title":"Nat Hum Behav"},{"issue":"1","key":"10.1016\/j.beem.2024.101921_bib66","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1089\/trgh.2016.0036","article-title":"Varied reports of adult transgender suicidality: synthesizing and describing the peer-reviewed and gray literature","volume":"2","author":"Adams","year":"2017","journal-title":"Transgend Health"},{"key":"10.1016\/j.beem.2024.101921_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.socscimed.2021.114143","article-title":"Social relationship experiences of transgender people and their relational partners: a meta-synthesis","volume":"282","author":"Lewis","year":"2021","journal-title":"Soc Sci Med"},{"issue":"2","key":"10.1016\/j.beem.2024.101921_bib68","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1515\/nf-2020-0007","article-title":"Neuroscience in transgender people: an update","volume":"26","author":"Kiyar","year":"2020","journal-title":"Neuroforum"},{"issue":"4","key":"10.1016\/j.beem.2024.101921_bib69","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvab011","article-title":"Hormone therapy, mental health, and quality of life among transgender people: a systematic review","volume":"5","author":"Baker","year":"2021","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.beem.2024.101921_bib70","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.2147\/NDT.S95310","article-title":"The effect of cross-sex hormonal treatment on gender dysphoria individuals' mental health: a systematic review","volume":"12","author":"Costa","year":"2016","journal-title":"Neuropsychiatr Dis Treat"}],"container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X24000757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X24000757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T04:12:07Z","timestamp":1726373527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X24000757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":70,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1521690X24000757"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2024.101921","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gender-affirming hormone treatment modalities for transfemale & non-binary transfeminine individuals: A UK perspective","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2024.101921","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101921"}}